Panbela Announces Issuance Of New Patent In Chile For Claims Of A Novel Process For The Production Of Flynpovi
Portfolio Pulse from Happy Mohamed
Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced the issuance of a new patent in Chile for its product Flynpovi, a fixed dose formulation of eflornithine and sulindac developed in collaboration with Sanofi. The patent, which is valid until 2036, has also been issued in the US, Australia, Mexico, and Taiwan. Flynpovi is Panbela's lead investigational product for the treatment of Familial Adenomatous Polyposis (FAP).
September 05, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The issuance of a new patent in Chile for Panbela's product Flynpovi expands the company's global patent portfolio and supports its clinical programs. This could potentially increase the company's market share and revenue in the future.
The issuance of a new patent for a company's product typically protects the company's intellectual property rights, prevents competitors from copying the product, and potentially increases the company's market share and revenue. In this case, the new patent for Panbela's product Flynpovi in Chile expands the company's global patent portfolio and supports its clinical programs, which could potentially increase the company's market share and revenue in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100